fulvestrant has been researched along with mdv 3100 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angstadt, S; Dahut, M; Fousek, K; Hamilton, DH; Horn, LA; Palena, C; Qin, H; Schlom, J | 1 |
1 other study(ies) available for fulvestrant and mdv 3100
| Article | Year |
|---|---|
Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis.
Topics: Fulvestrant; Humans; Male; Prostate; Prostatic Neoplasms, Castration-Resistant; Receptors, Estrogen | 2023 |